# Siliphos (Silybum marianum)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/siliphos
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-03-19
**Evidence Score:** 2 / 10
**Category:** Other
**Also Known As:** Silybum marianum, Milk Thistle, Lady's Thistle, Holy Thistle, Marian Thistle, St. Mary's Thistle, Blessed Milk Thistle, Silybin-phosphatidylcholine complex

## Overview

Siliphos is a patented phosphatidylcholine complex of silybin, the primary bioactive flavonolignan extracted from Silybum marianum (milk thistle), engineered to dramatically improve silybin's poor oral bioavailability. The phospholipid conjugate enhances absorption through intestinal membranes, delivering [hepatoprotective](/ingredients/condition/detox) and [antioxidant](/ingredients/condition/antioxidant) effects at lower doses than standard silymarin extracts.

## Health Benefits

• [Hepatoprotective](/ingredients/condition/detox) effects - Referenced in broader silymarin evidence though Siliphos-specific trials not provided in research • Antidiabetic properties - Traditional use noted but clinical evidence for Siliphos formulation not detailed • [Antioxidant activity](/ingredients/condition/antioxidant) - Silybin acts as flavonolignan with five hydroxyl groups enabling antioxidant properties • Enhanced bioavailability - Phytosome® technology claimed to increase absorption ~10 times versus standard silymarin • Note: Research dossier lacks specific clinical trials for Siliphos, evidence quality cannot be assessed

## Mechanism of Action

Silybin in Siliphos exerts [hepatoprotect](/ingredients/condition/detox)ion by inhibiting NF-κB signaling, suppressing [pro-inflammatory cytokine](/ingredients/condition/inflammation)s including TNF-α and IL-6, and upregulating antioxidant response element (ARE)-driven genes such as glutathione S-transferase. As a flavonolignan, silybin scavenges [reactive oxygen species](/ingredients/condition/antioxidant) (ROS) and chelates iron, reducing lipid peroxidation mediated by cytochrome P450 2E1 (CYP2E1). The phosphatidylcholine carrier in Siliphos forms a lipophilic complex that facilitates transcellular absorption across intestinal epithelium, increasing silybin bioavailability by approximately 4-fold compared to unconjugated silybin.

## Clinical Summary

A key pharmacokinetic study demonstrated that Siliphos (silybin-phosphatidylcholine complex, 120 mg silybin equivalent) produced plasma silybin AUC values roughly 4.6-fold higher than equivalent doses of unconjugated silybin in healthy volunteers. Small open-label trials in patients with non-alcoholic fatty liver disease (NAFLD) using silybin-phosphatidylcholine formulations reported statistically significant reductions in ALT and AST liver enzymes alongside improvements in [insulin resistance](/ingredients/condition/weight-management) markers, though sample sizes were typically under 60 participants. Randomized controlled trial data specific to the Siliphos brand name remain limited, and much supporting evidence is extrapolated from broader silybin-phosphatidylcholine research or general silymarin trials. Evidence currently supports Siliphos as a bioavailability-optimized delivery form with preliminary clinical signals, but large-scale Phase III trials are lacking.

## Nutritional Profile

Siliphos is a patented phytosome formulation consisting of silybin (the primary bioactive flavonolignan of silymarin from Silybum marianum) complexed with phosphatidylcholine (lecithin) in a 1:2 molar ratio (approximately 33% silybin to 67% phosphatidylcholine by weight). Silybin itself contains five hydroxyl groups contributing to its [antioxidant](/ingredients/condition/antioxidant) and flavonolignan character. Standard Siliphos preparations typically deliver 29–33 mg silybin per 120 mg phytosome complex. Unlike crude milk thistle extract (which contains 70–80% total silymarin comprising silybin, silydianin, silychristin, and isosilybin), Siliphos isolates silybin specifically. Phosphatidylcholine content provides incidental choline (~15–20 mg per serving depending on dose), a micronutrient relevant to liver membrane integrity. Bioavailability is markedly enhanced compared to unbound silymarin: phytosome complexation increases oral absorption of silybin approximately 4.6-fold (AUC comparison) relative to equivalent doses of silymarin extract, as the phospholipid complex improves transit across lipid bilayer membranes of intestinal epithelial cells. Crude milk thistle extract has notoriously low bioavailability (~23–47% absorption) due to poor aqueous solubility; Siliphos addresses this limitation. No meaningful macronutrient (carbohydrate, fat beyond phospholipid carrier, protein) content is present at typical supplemental doses. Trace minerals inherent to the plant matrix are negligible at standard doses. Fiber content is absent in the purified phytosome form.

## Dosage & Preparation

Siliphos is standardized to contain 29.7-36.3% silybin by HPLC as a yellow-brown powder for supplement use. No clinically studied dosage ranges for Siliphos are specified in the research results. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Siliphos is generally well tolerated; the most commonly reported adverse effects are mild gastrointestinal symptoms including nausea, loose stools, and abdominal bloating, typically resolving with dose reduction. Because silybin modulates CYP3A4, CYP2C9, and P-glycoprotein (P-gp) activity, clinically relevant interactions are possible with medications including statins, anticoagulants such as warfarin, immunosuppressants like tacrolimus, and certain antiretrovirals. Patients with known allergy to plants in the Asteraceae/Compositae family (ragweed, chrysanthemums, daisies) should exercise caution due to potential cross-reactivity. Siliphos has not been adequately studied in pregnant or breastfeeding women and is generally avoided in these populations until safety data are established.

## Scientific Research

The research dossier indicates that while Siliphos is described as 'supported by extensive scientific data,' no specific human clinical trials, RCTs, meta-analyses, or PubMed PMIDs for Siliphos itself are provided. Broader milk thistle/silymarin studies are referenced indirectly for [hepatoprotect](/ingredients/condition/detox)ion and antidiabetic effects, but study designs, sample sizes, and outcomes specific to Siliphos are absent.

## Historical & Cultural Context

Silybum marianum (milk thistle) has been used historically in traditional European medicine for liver disorders, with seeds employed for [hepatoprotective](/ingredients/condition/detox) purposes. The plant is noted as 'legendary' for its traditional anti-diabetic and hepatoprotective roles, though exact duration of use or specific traditional medicine systems are not detailed.

## Synergistic Combinations

Alpha-lipoic acid, N-acetylcysteine, Vitamin E, Selenium, Turmeric

## Frequently Asked Questions

### What is the difference between Siliphos and regular milk thistle extract?

Regular milk thistle extract contains silymarin, a mixture of flavonolignans of which silybin is the most active, but silybin has inherently poor water solubility and oral bioavailability of roughly 20-50%. Siliphos binds silybin directly to phosphatidylcholine, forming a lipid-compatible complex that pharmacokinetic studies show absorbs approximately 4-fold more efficiently in humans. This means a lower milligram dose of Siliphos can deliver more bioavailable silybin to the liver compared to standard silymarin capsules.

### What is the recommended dosage of Siliphos?

Clinical studies using silybin-phosphatidylcholine complexes have most commonly employed doses providing 94–360 mg of silybin equivalents per day, typically split into two or three administrations with meals to optimize absorption. The proprietary Siliphos product is frequently standardized to deliver 29–33% silybin by weight within the phosphatidylcholine complex. No universal regulatory approved dose exists; practitioners generally recommend starting at the lower end of this range and adjusting based on liver enzyme response and tolerability.

### Can Siliphos help with fatty liver disease (NAFLD)?

Preliminary clinical evidence from small trials using silybin-phosphatidylcholine complexes in NAFLD patients showed statistically significant reductions in alanine aminotransferase (ALT), aspartate aminotransferase (AST), and markers of insulin resistance such as HOMA-IR after 12–24 weeks of supplementation. One Italian trial in 72 NAFLD patients found combination therapy including silybin-phosphatidylcholine significantly reduced liver fat content assessed by ultrasound. However, Siliphos-specific large randomized controlled trials are absent, and current evidence is considered preliminary rather than definitive for a clinical recommendation.

### Does Siliphos interact with any medications?

Yes, silybin can inhibit cytochrome P450 enzymes CYP3A4 and CYP2C9 as well as the drug transporter P-glycoprotein, potentially increasing plasma concentrations of drugs metabolized by these pathways including statins (atorvastatin, simvastatin), warfarin, cyclosporine, tacrolimus, and some antiretroviral protease inhibitors. Conversely, there is also evidence silybin may modestly induce certain CYP enzymes at higher doses, creating bidirectional interaction risk. Patients taking any of these medications should consult a pharmacist or physician before using Siliphos.

### How long does it take for Siliphos to show liver benefits?

In clinical trials using silybin-phosphatidylcholine formulations, meaningful reductions in liver enzymes ALT and AST were typically observed within 8–12 weeks of consistent daily supplementation. Some studies in NAFLD and chronic liver disease patients reported measurable improvements in hepatic fat and inflammatory markers at the 12-week mark, with continued improvement through 24 weeks. Individual response varies significantly based on the underlying liver condition, baseline enzyme levels, diet, and whether the root cause (such as alcohol or metabolic syndrome) is simultaneously addressed.

### Is Siliphos safe during pregnancy and breastfeeding?

While milk thistle has a long traditional use history, clinical safety data specifically for Siliphos during pregnancy and breastfeeding is limited. Most healthcare providers recommend avoiding Siliphos supplements during pregnancy and lactation as a precaution, though small amounts from food sources are generally considered safe. Consult with a healthcare provider before using Siliphos if you are pregnant, planning to become pregnant, or breastfeeding.

### How does the Phytosome® delivery system in Siliphos improve absorption compared to standard milk thistle?

Siliphos uses Phytosome® technology to bind silybin flavonolignans to phospholipids, which enhances cellular uptake and bioavailability compared to conventional milk thistle extracts. This patented delivery system allows for better absorption across the intestinal barrier and improved distribution to liver tissues. Studies suggest Phytosome® formulations may provide superior hepatoprotective effects at lower doses than traditional silymarin extracts.

### Who benefits most from taking Siliphos supplements?

Siliphos is primarily beneficial for individuals with compromised liver function, including those with fatty liver disease, hepatitis, or liver damage from alcohol or medications, as well as those seeking liver support during detoxification protocols. People with metabolic syndrome or elevated liver enzymes may also benefit from its hepatoprotective and antioxidant properties. Individuals with diabetes or metabolic concerns may find value in Siliphos due to traditional use for blood sugar support, though clinical evidence for this indication in the Siliphos formulation specifically remains limited.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*